1. Introduction {#s0005}
===============

Parkinson\'s disease (PD) is a progressive neurodegenerative disease characterised by depletion of pigmented dopaminergic neurons of the substantia nigra pars compacta (SNc) ([@bb0215]). The correlation of the dopaminergic cell loss in SN with the progressive symptoms of PD ([@bb0125]) makes SN imaging promising for biomarker search in PD. The clinical diagnosis of PD is based on the application of the Queen Square Parkinson Brain Bank Criteria with accuracy rates varying from excellent in specialised centres ([@bb0105]) to 15--25% false positive rate in some community studies ([@bb0135; @bb0190]).

In the last two decades the search for imaging biomarkers of PD has revealed a variety of promising techniques including magnetic resonance imaging (MRI) and transcranial sonography (TCS). PD associated structural brain changes were reported for both modalities throughout many different brain regions with a wide variety of accuracy and repeatability ([@bb0005; @bb0015]). However, none of these techniques to date accomplished the required accuracy and reliability to justify introduction in standard clinical practice or as part of interventional clinical trials. Particularly promising, but equally controversial, are results obtained with diffusion tensor MR imaging (DTI) to probe SN diffusion characteristics.

MRI diffusion metrics assess the random movement of water protons in terms of overall extent (mean diffusivity, MD) and orientational dependence (fractional anisotropy, FA). The complex ultrastructure of the brain results in a distinctive pattern of diffusion restriction and anisotropy against which subtle alterations in intra- and extracellular diffusion barriers can be well described. Neurodegenerative cell loss removes diffusion barriers and their orientational dependence, which results in increased diffusivity and reduced anisotropy as demonstrated in a number of neurodegenerative diseases. In atypical parkinsonism, regional diffusional abnormalities enable the distinction of multi-system atrophy and progressive supranuclear palsy from PD and control patients ([@bb0020; @bb0185; @bb0200]).

In order to differentiate PD from healthy controls, several studies reported alterations of nigral FA, MD or the related apparent diffusion coefficient (ADC) using manual or 'semi-manual' delineation of the SN. Recently, a remarkable diagnostic accuracy was reported in a 3 T DTI study for a latero-dorsal sub-region of the SN ([@bb0220]). The authors suggested that their unique diagnostic accuracy resulted from the resolution and the location of the region of interest (ROI). The latter is plausible due to the known spatial heterogeneity of dopaminergic cell loss, predominantly affecting nigrosome 1 in the latero-dorsal aspect of the SNc ([@bb0045]). In addition, the borders of the SN are not well delineated and reported studies use different non-standardised landmarks.

In this study we aimed to evaluate the diagnostic accuracy of high resolution nigral DTI to distinguish PD from controls using a selection of ROI as well as voxel-based group analysis. To determine whether nigral diffusion metrics (FA and MD) qualify as candidate biomarkers we undertook a systematic review and meta-analysis of continuous data to estimate their 'relative disease effect size' (D~ES~) for PD.

2. Material and methods {#s0010}
=======================

2.1. Diffusion tensor MRI case--control study {#s0030}
---------------------------------------------

The study was approved by the local Ethics Committee and Research and Development department. All participants gave written informed consent prior to enrolment into the study. 67 participants were investigated, 8 were excluded from further analysis due to technical artefacts/factors or significant cognitive impairment. 32 patients fulfilling the UK Brain Bank criteria for PD were recruited from movement disorders clinics at two local NHS trusts. 27 age and gender matched controls were recruited from spouses, friends or within the university. The subjects underwent the Addenbrooke\'s cognitive examination (ACE) test battery ([@bb0010]) and were excluded if they had a history of cognitive impairment or an ACE score of \< 80. Five controls did not complete the ACE test battery, however, these participants did not have any past cognitive problems nor a neurological, neurosurgical or psychiatric history. Parkinson\'s disease severity was scored using the UPDRS ([@bb0260]) and Hoehn and Yahr staging ([@bb0090]).

MR imaging was performed at 3 T (Achieva scanner, Philips Medical Systems, Best, Netherlands) with a standard eight-channel head coil. Axial diffusion tensor imaging was obtained using a single shot fat saturated spin echo EPI (TR/TE = 7415/60 ms, 52 slices, acquisition matrix of 112 × 112 with pixel size of 2 × 2 × 2 mm^3^, interpolated to 1 × 1 × 2 mm^3^, sense factor of 2, partial Fourier factor of 0.7, 32 diffusion gradient directions with b = 1000 s/mm^2^, and three repeats of b = 0). Patients were assessed and scanned whilst medicated.

### 2.1.1. Substantia nigra regional manual measurements {#s0035}

The image processing was completed using the diffusion tools in the FSL 4.1.0 software package ([@bb0110; @bb0240]). DTI processing consisted of motion correction, affine registration to reduce the effects of eddy currents, and calculation of the diffusion tensor parametric maps of MD and FA.

Regions-of-interest were manually drawn by an experienced researcher with 5 years of experience in PD imaging research to outline the SN using JIM software ([www.xinapse.com](http://www.xinapse.com){#ir0050}) or an in house developed image analysis software package NeuRoi (Dr C. Tench, University of Nottingham, UK). Anatomical landmarks were identified on the T2 weighted image for the red nucleus as hypointense structure, and on FA maps for the cerebral peduncle as hyperintense area and used to constrain the lateral border of the SN. Two types of SN and separate control ROI were used ([Fig. 1](#f0020){ref-type="fig"}): 1. Small SN ROI --- three ROI measuring 2 × 2 × 2 mm^3^ (4 pixels in plane) placed over each of the T2 hypointense SN ventrally, medially and dorsally on two slices (lowest slice containing the red nucleus and one below) in accordance with anatomical landmarks and dimensions used in [@bb0220], 2. Large SN ROI --- Manual outlining of the hypointense region between the cerebral peduncles and posterior tegmentum on three slices (two at the lower level of the red nucleus and one below in accordance to landmarks and variable size in ([@bb0065])). 3. Control region --- 2 × 2 × 2 mm^3^ ROI placed in the cerebral peduncles on the same slices as analysis 2.

Reproducibility of manual SN ROI placement was assessed by calculation of intraclass correlation coefficients (ICC) for inter-rater (2nd researcher with 5 years experience in MRI research in PD) and intra-rater variability in 20 random subjects with a minimum of 12 weeks of interval between analyses. 'Absolute agreement' coefficients were calculated assuming a two-way random effect model with random people and measurement effects.

### 2.1.2. Voxel-based analysis {#s0040}

Individual FA images were aligned to FMRIB58_FA standard-space template and corresponding transformation matrixes were applied on MD images using FMRIB\'s Nonlinear Registration Tool as part of the FSL 4.1.0 software package (FMRIB\'s software library, <http://www.fmrib.ox.ac.uk/fsl/> ([@bb0110; @bb0240])).

The spatially normalized MD and FA images were smoothed with a 8-mm isotropic Gaussian kernel to reduce the level of noise and correct the misalignment. Statistical comparisons were performed using statistical parametric mapping (SPM5, <http://www.fil.ion.ucl.ac.uk/spm>) by a two sample t-test between controls and patients with age as covariates of no interest. An uncorrected p \< 0.001 at voxel level for multiple comparisons were considered as significant.

### 2.1.3. Statistics {#s0045}

Statistical tests were performed using IBM® SPSS® for windows (version 19.0). Demographics were compared between all patients and controls using analysis of variance or chi-square test. Non-parametric tests were used for group comparisons if the data was found to be not normally distributed. Results from right and left SN measures were averaged. Values are given as mean ± SD unless stated otherwise; significance was defined at p \< 0.05.

2.2. Systematic review and meta-analysis {#s0050}
----------------------------------------

To identify relevant literature three databases and reference lists of articles were searched (PubMed, ScienceDirect and EMBASE 1980--2013) in accordance to the 'preferred reporting items for systematic reviews and meta-analysis' (PRISMA) statement ([@bb0115]). The search was performed independently by two researchers using multiple Medical Subject Headings.

Out of 25 reviewed articles 14 were excluded for the following reasons: 10 publications because of missing description of regional SN DTI measures, 2 publications because of overlapping participant populations with studies included in the meta-analysis, 2 publications because of a missing healthy control arm.

Apart from FA, MD and ADC measures the following data was extracted from the publications if available: PD and control group age, measure of PD disease severity (HY-stage or UPDRS), Scanner make, scanner field strength, number of channels within the receiver head coil, number of diffusion gradient directions, voxel size, DTI post-processing software, motion and eddy current correction and method of ROI placement. In case of visual identification and manual outlining of the SN the method of ROI placement was classified as 'manual'. In case of manual identification and automated digital boundary detection by changes in gradients ([@bb0170]) or manual identification and SN sub-categorisation into pars compacta and pars reticulata by using connectivity measures ([@bb0140]) the ROI placement was classified as 'semi-manual'.

Where available, mean and standard deviation measures of FA, MD or ADC were extracted. Results of two studies reporting nigral ADC values instead of MD values were also included into the meta-analysis. Even if the absolute values of ADC and MD differ, they are both descriptors of diffusivity with averaged out factors of directional diffusivity (anisotropy). For calculation of the effect size within the meta-analysis the relative difference of MD or ADC when comparing PD and controls was included. In one case only non-normal distribution measures such as median, range and quartiles were presented ([@bb0030]). To allow comparability within the meta-analysis, mean and standard deviation values were estimated by using previously published conversion techniques ([@bb0100]).

In case of multiple publications on the same or overlapping study populations, the study describing results in the largest number of subjects was included in the meta-analysis. If values were only available as part of a diagram the values were extracted by manual measurement (using an image editing tool, GIMP, version 2.8, from [www.gimp.org](http://www.gimp.org){#ir0065}) on two separate occasions (4 weeks apart) and averaged. In two studies the SN was subdivided into three small regions of interest (rostral, middle and caudal) and only values of the sub-regions of the SN were described ([@bb0160; @bb0220]). To allow comparability within the meta-analysis the mean FA over all three regions was calculated. Also for the purpose of the meta-analysis, the averaged results of subdivided ROI measures of this study were included (according to the data included from [@bb0220]).

For further details see the supplementary material in Appendix A.

The disease effect size (D~ES~) was defined as the standardised difference of nigral DTI measures between the PD patient group and healthy volunteer group using Cohen\'s d ([@bb0040]). We used MetaAnalyst software (MetaAnalyst, version: Beta 3.13, Tufts Medical Centre ([@bb0265])) for continuous data using the DerSimonian and Laird random effect model and the assumption of unequal within study variances. I^2^ --- values were computed as a measure of in between study heterogeneity ([@bb0085]).

3. Results {#s0015}
==========

3.1. Case--control DTI study {#s0055}
----------------------------

One participant had to be excluded because of significant cognitive impairment (ACE score 75), 7 participants were excluded because of usage of a previous DTI scanning protocol and/or scanning artefacts. The remainder 59 subjects did not show demographic differences (32 PD, age: 64.8 ± 11.8, 16 male and 27 controls, age 59.9 ± 10.5, 11 male). In 5 healthy controls the ACE was not obtained, however, these subjects had no past cognitive problems and no neurological, neurosurgical or psychiatric history. There was no difference in cognitive performance in the subjects assessed with ACE (n = 32, PD: 92.7 ± 4.8; n = 22 Controls 94.3 ± 6.4, n.s.). Patients had mild to moderate degrees of PD severity: mean UPDRS, 26.1 ± 13.9; mean HY score, 1.7 ± 0.9.

Independent of the type of ROI (small ROI of analysis 1 or large ROI of analysis 2, see [Fig. 1](#f0020){ref-type="fig"}) the intraclass correlation coefficients for intra-rater and inter-rater concordance were high with correlation coefficients ranging from 0.6 to 0.85 (all p ≤ 0.003). There were no differences in FA or MD in the control region between PD and controls excluding technical bias.

There were no differences in nigral FA between patients with PD and controls in the whole SN or the small dorsal SN known to be the most affected part. In contrast, a significant increase in nigral MD in PD was found independent of ROI used for analysis ([Table 1](#t0020){ref-type="table"}).

Voxel based analysis of co-registered FA and MD maps did not reveal any differences in nigral DTI measures when comparing patients with PD to controls (uncorrected p \< 0.001).

3.2. Systematic review and meta-analysis {#s0060}
----------------------------------------

The search of three databases revealed 169 unique database entries. After applying in- and exclusion criteria 25 articles were reviewed out of which 11, including 10 studies for FA measures and 9 studies for MD or ADC measures were retained. The results presented above were added as a further study to the meta-analysis. Relevant publications and study intrinsic technical factors are listed in [Table 2](#t0025){ref-type="table"}. Population details of the included studies are listed in the supplements ([Inline Supplementary Table S1](#b0005){ref-type="boxed-text"}).

The search of three databases revealed 169 unique database entries. After applying in- and exclusion criteria 25 articles were reviewed out of which 11, including 10 studies for FA measures and 9 studies for MD or ADC measures were retained. The results presented above were added as a further study to the meta-analysis. Relevant publications and study intrinsic technical factors are listed in [Table 2](#t0025){ref-type="table"}. Population details of the included studies are listed in the supplements (Inline Supplementary Table S1).

Inline Supplementary Table S1Table S1Participant details of studies included in the meta-analysis.Study nameControlsPD patientsAverage age PD and controlNAgeNAgeUPDRSHY stage[@bb0160]1260.8 ± 8.51160.4 ± 9.323.5 ± 9.51--360.6[@bb0060]2859.8 ± 7.04060.8 ± 8.223.5 ± 15.1\
(UPDRS III)1.8 ± 0.660.4[@bb0205]1360136432.5 ± 6.11.76 ± 0.2662[@bb0170]1455.2 ± 6.21456 ± 4.8?1.3 ± 0.4255.6[@bb0235]3065 ± 5.13064.5 ± 3.433.6 ± 14.1?64.8[@bb0250]2067.2 ± 81267.4 ± 826.3 ± 12.2?67.3[@bb0140]1064.4 ± 9.91063.7 ± 6.7?2.3 ± 0.6764.1[@bb0150]2257.4 ± 9.73061.9 ± 11.112.0 ± 5.91.66 ± 0.4859.7[@bb0080]1058.1 ± 81063.8 ± 15.720.5 ± 8.3?61[@bb0220]14581457.2 ± 9.618 ± 8.11.71 ± 0.4657.6[@bb0030]7861.9 ± 9.37363.6 ± 9.8?2.462.8This data2759.9 ± 10.53264.8 ± 11.825.4 ± 13.71.7 ± 0.962.5[^1]Inline Supplementary Table S1

Inline Supplementary Table S1 can be found online at [http://dx.doi.org/10.1016/j.nicl.2013.10.006](10.1016/j.nicl.2013.10.006){#ir0070}.

### 3.2.1. Meta-analysis of PD induced nigral FA changes {#s0065}

The initial meta-analysis included nigral FA measures in a population of 547 subjects (n = 268 controls, n = 279 PD). We found a highly significant PD induced nigral FA reduction with an estimated weighted pooled disease effect size of − 0.90 (p \< 0.0001, Forrest plot see [Fig. 2](#f0005){ref-type="fig"}, values of individual studies see the supplements, [Inline Supplementary Table S2](#b0010){ref-type="boxed-text"}). However, review of the heterogeneity measures revealed a very high level of in-between study result variation (I^2^ = 86%). To assess for potential causes of the observed high variability of study results an exploratory D~ES~ regression analysis with the categories of field strengths, DTI-directions, voxel-size, relative disease severity and mean age as independent variables was performed. This did not reveal any significant dependence of D~ES~ on these factors (smallest p = 0.43) but is of limited value due to the small number of included studies.

The initial meta-analysis included nigral FA measures in a population of 547 subjects (n = 268 controls, n = 279 PD). We found a highly significant PD induced nigral FA reduction with an estimated weighted pooled disease effect size of − 0.90 (p \< 0.0001, Forrest plot see [Fig. 2](#f0005){ref-type="fig"}, values of individual studies see the supplements, Inline Supplementary Table S2). However, review of the heterogeneity measures revealed a very high level of in-between study result variation (I^2^ = 86%). To assess for potential causes of the observed high variability of study results an exploratory D~ES~ regression analysis with the categories of field strengths, DTI-directions, voxel-size, relative disease severity and mean age as independent variables was performed. This did not reveal any significant dependence of D~ES~ on these factors (smallest p = 0.43) but is of limited value due to the small number of included studies.

Inline Supplementary Table S2Table S2FA D~ES~ of studies included into the initial meta-analysis of nigral FA changes in PD.Study namePD patientsControls95% confidence intervalNMean FASDNMean FASDDisease effect size (D~ES)~SELowerUpper[@bb0160]110.430.04120.440.03− 0.2630.419− 1.0850.559[@bb0060]400.490.05280.530.04− 0.9150.259− 1.422− 0.407[@bb0205]130.370.04130.410.02− 1.2220.43− 2.064− 0.379[@bb0170]140.420.03140.450.03− 1.0910.407− 1.889− 0.293[@bb0235]300.710.10300.660.100.520.2630.0051.034[@bb0250]120.360.05200.490.07− 2.1690.46− 3.071− 1.267[@bb0140]100.340.07100.370.07− 0.3140.45− 1.1970.568[@bb0150]300.500.04220.530.03− 0.7160.29− 1.284− 0.148[@bb0220]140.440.02140.540.02− 5.5410.856− 7.219− 3.862[@bb0030]730.400.03780.420.03− 0.4140.165− 0.736− 0.091This study320.440.05270.450.05− 0.1960.262− 0.7090.317[^2]Inline Supplementary Table S2

Inline Supplementary Table S2 can be found online at [http://dx.doi.org/10.1016/j.nicl.2013.10.006](10.1016/j.nicl.2013.10.006){#ir0075}.

Interestingly, we found a strong variation of the mean nigral FA in the control populations between the different studies. Moreover, the strongest variation in D~ES~ was found in studies with the highest control FA values ([Fig. 3](#f0010){ref-type="fig"}). We therefore repeated the meta-analysis after exclusion of those studies with unexpected high FA value in SN based on a normative value derived from a freely available standard reference DTI atlas of 24 healthy adults (SRI24, [@bb0165]). ROI were drawn as described above and averaged over duplicate measures two weeks apart which revealed a maximum mean nigral FA of 0.47. We hence chose to exclude studies reporting nigral FA ≥ 0.48 in controls. This reduced the between study heterogeneity to an acceptable level (I^2^ = 28%) for the 6 finally included studies (307 subjects, n = 154 controls and n = 153 PD) resulting in a pooled weighted disease effect size of − 0.5 (95% CI: − 0.8 to − 0.2, p = 0.22, [Inline Supplementary Figure S1](#b0015){ref-type="boxed-text"}) which proved non-significant.

Interestingly, we found a strong variation of the mean nigral FA in the control populations between the different studies. Moreover, the strongest variation in D~ES~ was found in studies with the highest control FA values ([Fig. 3](#f0010){ref-type="fig"}). We therefore repeated the meta-analysis after exclusion of those studies with unexpected high FA value in SN based on a normative value derived from a freely available standard reference DTI atlas of 24 healthy adults (SRI24, [@bb0165]). ROI were drawn as described above and averaged over duplicate measures two weeks apart which revealed a maximum mean nigral FA of 0.47. We hence chose to exclude studies reporting nigral FA ≥ 0.48 in controls. This reduced the between study heterogeneity to an acceptable level (I^2^ = 28%) for the 6 finally included studies (307 subjects, n = 154 controls and n = 153 PD) resulting in a pooled weighted disease effect size of − 0.5 (95% CI: − 0.8 to − 0.2, p = 0.22, Inline Supplementary Figure S1) which proved non-significant.

Inline Supplementary Figure S1Fig. S1FA disease effect size Forest plot after excluding studies with an unexpected high FA measure in the control population.Forest plot of the computed diseases effect sizes (DES, x-axis) of studies included into the repeated meta-analysis on fractional anisotropy measures of the SN when excluding 5 studies with unexpected high control group FA measures. All included studies demonstrate a decrease of FA in PD patients as indicated by a negative DES. The estimated pooled weighted DES was − 0.5 but did not reach the significance level (p = 0.22).

Inline Supplementary Fig. S1 can be found online at [http://dx.doi.org/10.1016/j.nicl.2013.10.006](10.1016/j.nicl.2013.10.006){#ir0080}.

### 3.2.2. Meta-analysis of PD induced nigral MD changes {#s0070}

The meta-analysis of MD or ADC --- SN measures included a population of 471 subjects (n = 236 controls, n = 235 PD). Over all studies there was a non-significant increase in MD/ADC of the SN when comparing PD patients to controls (see also Forest plot: [Fig. 4](#f0015){ref-type="fig"}). The pooled weighted disease effect size over all studies was estimated to be + 0.26 (95% CI: 0.028--0.497, p = 0.17). Computation of heterogeneity measures revealed an acceptable level of in between study heterogeneity (I^2^ = 30%, [Inline Supplementary Table S3](#b0020){ref-type="boxed-text"}).

The meta-analysis of MD or ADC --- SN measures included a population of 471 subjects (n = 236 controls, n = 235 PD). Over all studies there was a non-significant increase in MD/ADC of the SN when comparing PD patients to controls (see also Forest plot: [Fig. 4](#f0015){ref-type="fig"}). The pooled weighted disease effect size over all studies was estimated to be + 0.26 (95% CI: 0.028--0.497, p = 0.17). Computation of heterogeneity measures revealed an acceptable level of in between study heterogeneity (I^2^ = 30%, Inline Supplementary Table S3).

Inline Supplementary Table S3Table S3MD D~ES~ of studies included into the meta-analysis of PD induced nigral MD changes.Study namePD patientsControl95% confidence intervalNMean MD or (ADC)SDNMean MD or (ADC)SDDisease effect size (D~ES)~SELowerUpperWeight[@bb0160]11(2.41)0.171512(2.345)0.12950.4310.423− 0.3981.2590.049[@bb0205]130.8140.106130.7960.0660.2040.393− 0.5670.9750.057[@bb0250]^⁎^129.9450.615209.491.3150.410.369− 0.3141.1330.064[@bb0235]300.680.15300.720.13− 0.2850.26− 0.7940.2240.13[@bb0170]140.840.048140.7930.3790.1740.379− 0.5680.9160.061[@bb0140]100.980.139100.93110.1660.3190.45− 0.5631.2020.043[@bb0150]300.7780.0805220.7540.05080.3450.283− 0.2090.8990.109[@bb0080]100.790.08100.740.040.7910.466− 0.1231.7040.04[@bb0030]73(7.3273)0.79578(7.32)0.6510.010.163− 0.3090.3290.33Own dataset320.8010.102270.7280.0640.8410.2730.3061.3760.117[^3]Inline Supplementary Table S3

Inline Supplementary Table S3 can be found online at [http://dx.doi.org/10.1016/j.nicl.2013.10.006](10.1016/j.nicl.2013.10.006){#ir0085}.

4. Discussion {#s0020}
=============

4.1. PD induced nigral MD increase {#s0075}
----------------------------------

In our prospective case--control study we found a significant increase in nigral MD in patients with PD compared to matched controls when using ROI to outline the SN. There were no significant MD differences when using a voxel-based analysis approach. The meta-analysis of PD induced nigral MD changes did also not confirm a significant disease effect.

Regional increases in diffusivity metrics like ADC or MD, are useful markers of neurodegeneration that can help to distinguish the parkinsonian variant of MSA from PD ([@bb0020; @bb0185; @bb0200]). It is less clear whether increased diffusivity can also index PD induced nigral pathology. Strong nigral MD increases were found in one animal model of PD ([@bb0025]), while other studies found less or no disease effect ([@bb0210; @bb0225]). This is largely in line with our findings of a small increase in nigral MD, but no effect in the meta-analysis or VBA. A tendency of increased MD or ADC can be seen in most studies, and the lack of observable pooled disease effect may be a type II error. Alternatively, these inconsistencies may reflect differences in patient characteristics or ROI selection. Nevertheless, against the criteria of identifying promising biomarkers, nigral MD measurements have limited value to reliably differentiate PD pathology from the healthy brain on a case by case basis.

4.2. PD induced nigral FA change {#s0080}
--------------------------------

We did not observe a PD induced reduction of nigral FA in our studied population. This observation is in contrast with some recent publications claiming very high diagnostic accuracy ([@bb0220]), but well in line with other reports showing small or no PD induced nigral FA decrease ([@bb0030; @bb0075; @bb0140]). A single study even reported an increase of nigral FA in PD patients ([@bb0235]). Interestingly in animal models of PD findings also range from increasing ([@bb0225]) to decreasing nigral FA ([@bb0025; @bb0210]). The research synthesis of the published literature assessing PD induced nigral FA changes revealed a significant FA reduction in the first instance (weighted pooled disease effect size of − 0.9, p \< 0.0001), however, we found a very high variation of results of the included studies which is reflected in an exceptionally large I^2^ of 86%. Evaluation of D~ES~ of individual studies demonstrate that our study findings of FA changes are well within the range of the majority of studies with overlapping confidence intervals between our and the pooled D~ES~. In contrast, the reported study by [@bb0220] and [@bb0235] need to be considered as outliers with D~ES~ and CI outside the range of results from the other 10 studies, and from each other.

A recently published meta-analysis by Cochrane and Ebmeier describes DTI changes in parkinsonian syndromes and found similar highly significant PD induced nigral FA reduction (D~ES~ = − 0.64, p \< 0.0001) but a much smaller variation in results comparing the different studies (I^2^ = 9.5%) ([@bb0035]). The reason for the difference in results of the two meta-analyses is likely due to two main reasons: The 1st reason is a difference in studies included in the two meta-analyses. Cochrane and Ebmeier included two studies not included in this meta-analysis, one by [@bb0245] which describes changes in peri-nigral FA rather than changes of the SN and a second one by [@bb0075] which did not find any PD induced nigral FA changes nor reported any relevant FA values (and was therefore excluded from this meta-analysis). Cochrane and Ebmeier for unknown reasons did not include the only study reporting a PD induced nigral FA increase by [@bb0235] which contributes largely to the variation of results we identified when comparing all studies. Further newer studies which were unpublished at the time of Cochrane\'s meta-analysis ([@bb0160; @bb0205]) and this study are included additionally in this meta-analysis. The 2nd reason for the observed differences is likely due to a variation of extracted values from included studies. When directly comparing the extracted values and Forest plots of the two meta-analyses study by study, there is a good correlation of effect sizes and CI for most of the studies. However, two studies with the largest effect sizes ([@bb0220; @bb0250]) differ in reported D~ES~ and CI. [@bb0220] used sub-regional SN analysis with values demonstrated in diagrams only which could explain a variation in value extraction for both analyses. [@bb0250], however, illustrated absolute SN FA measures including SD and p-values which seem to be underestimated in Cochrane and Ebmeier\'s meta-analysis. Therefore methodical differences are likely contributing to the dissimilar results of heterogeneity measures, however, by including new studies and solely focusing on nigral FA changes this meta-analysis provides new insights, specifically the large variation of observed nigral FA D~ES~ throughout the literature.

A potential factor contributing to the in this meta-analysis observed large in between study heterogeneity could be technical aspects resulting in limited quality of FA measurements. Indirect assessment of technical quality of published DTI studies is challenging. However, a preliminary exploratory regression analysis did not show an obvious association between field strength, number of diffusion directions and nigral FA in the control population of the studies. Further potential contributing factors are study population characteristics such as disease severity conceivably causing difference in D~ES~. However, a recent study demonstrating nigral FA changes in PD did not find any correlation of disease severity with FA changes ([@bb0060]) nor did we find an indication of disease severity related nigral FA changes on the exploratory regression analysis. We also investigated the influence of choice of ROI on nigral FA changes. The pars compacta of the substantia nigra (SNc) contains the cells that progressively deplete in PD. Delineation of the SNc on MRI *in vivo* is not standardised and varies from study to study using indirect landmark based techniques to outline the SN or SNc. This is causing considerable anatomical variability with some studies using small sub regions within the iron rich SN pars reticulate as ROI ([@bb0030; @bb0220]) whilst other studies outline the whole of the SN as ROI ([@bb0060]). Interestingly, [@bb0220] described the by far the largest D~ES~ when choosing a small ROI in the dorso-caudal region of the SN. Even when replicating these ROI we could not reproduce their finding nor could we or others ([@bb0180]) identify altered SN substructures when using an operator independent voxel-based analysis.

There was considerable variation in reported nigral FA of the control group across studies ranging from 0.37 to 0.7 which covered the entire range of reported nigral FA in patients. This highlights a larger between study heterogeneity in nigral control FA than potential disease effect pointing to either grossly different choice of region-of-interest or substantial technical differences. The SN is a grey matter nucleus, for which FA values as a measure of orientation dependence are expectedly small. FA values closer to 1 are expected to be found in highly organised white matter structures rather than poorly organised grey matter structures. The FA values of the hippocampal region in control populations in Alzheimer\'s disease studies for example range from 0.1 to 0.2 ([@bb0255; @bb0095; @bb0145]). The FA in the region of the basal ganglia like the globus pallidus, thalamus, caudate and putamen are reported in the range from 0.19 to 0.41 ([@bb0155]) which is also lower than most of the reported nigral control FA values. Iron deposition in the basal ganglia, specifically in the Substantia nigra increases with age ([@bb0050]) and this process is accelerated in PD ([@bb0120]) with some evidence that iron deposition even correlates with disease stage in PD([@bb0130]). The effect of iron increase on DTI measures like FA are poorly understood, however, age-dependent increase in putaminal iron deposition was found to significantly correlate to an increase of FA in the same region raising the possibility of iron deposition induced FA alterations. It is conceivable that accelerated nigral iron deposition in PD ([@bb0120; @bb0130]) affects FA measures and decreases observable differences when comparing PD patients and controls.

The bulk of between study heterogeneity in this meta-analysis of nigral FA changes was observed in studies reporting higher nigral FA values in healthy controls including the two studies with the largest effect size. This raises the possibility of the inclusion of peri-nigral fibre tracts into 'SN' ROI especially in studies with relative thick slices (4 mm in ^11^). In fact, FA changes of the white-matter closely related to the SN and within the basal ganglia have been well described ([@bb0245]). Also, the study using the most advanced segmentation of the SN reported the lowest FA in controls and did not find a significant disease effect ([@bb0140]). Therefore variation in size and placement of the ROI with resulting inclusion of adjacent white matter is likely to contribute to the large observed heterogeneity of FA-D~ES~. Exclusion of studies with unexpectedly high nigral FA in controls in our meta-analysis confirmed a non-significant PD induced nigral FA reduction.

This case--control study and meta-analysis of nigral DTI measures demonstrates that usage of nigral FA changes as biomarker of PD is neither reliable nor useful at this point in time. Even if there is some evidence of nigral FA decrease in some published studies, it is unclear if this is a true PD induced effect or rather due to other factors like inclusion of peri-nigral white matter or differences in iron deposition in the area of the SN. To clarify the diagnostic value of PD induced nigral FA alterations and development of this technique as PD biomarker future studies would need to address a range of issues:1.Confirmation and standardisation of anatomical position of SN/SNc ROI using magnetic resonance imaging. MR sequences demonstrating neuromelanin (black pigment of the SN) dependent contrast might be helpful to confirm the definite localisation of the SN pars compacta ([@bb0175; @bb0195]) and could be used to improve and/or standardize SN ROI placement.2.Assessment of influence of nigral iron deposition on FA changes and correlation to age related physiological SN changes.3.Assessment of validity and repeatability of nigral FA measures by assessing volunteers on varying scanner platforms.

4.3. Limitations of this study {#s0085}
------------------------------

In common with all literature searches and meta-analyses, publication practices may bias the results. Hence the reported mean D~ES~ is probably overestimated as unpublished negative study results are probably under-represented.

Due to the large heterogeneity of the results of studies included in the FA meta-analysis we decided to introduce a relative quality measure (atlas derived upper threshold for nigral FA value in the healthy population arm) to identify studies for inclusion in the final FA meta-analysis. This meta-analysis resulted in an acceptable distribution of study D~ES~, however, with the limitation that it is not entirely representative of all published studies in this field.

5. Conclusion {#s0025}
=============

In conclusion, this DTI study in 59 subjects together with the systematic review and meta-analysis of available published reports do not support nigral DTI metrics as useful diagnostic marker of PD at this point in time.

Appendix A. Supplementary data {#s0095}
==============================
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![Example of a DTI scan of a healthy control and ROI positions in the SN and control regions.\
Columns represent: 1st: T2 weighted b~0~ image; 2nd: colour coded map of the principle eigenvector of the diffusion matrix; 3rd: FA map; and 4th: MD maps. ROIs are demonstrated in the second row for small ROI (analysis 1) and in the third row for total SN and control ROI in the cerebral peduncle (analysis 2).](gr1){#f0020}

![Fractional anisotropy disease effect size Forest plot.\
Forest plot of the computed diseases effect sizes (D~ES~, x-axis) of studies included into the initial meta-analysis on fractional anisotropy measures of the substantia nigra when comparing PD patients and controls. All but one included studies demonstrate a decrease of nigral FA in PD patients as indicated by a negative D~ES~. The estimated pooled weighted D~ES~ was − 0.9 was highly significant (p \< 0.0001), however, there was a large heterogeneity of study results (I^2^ = 86%).](gr2){#f0005}

![Scatter-plot of D~ES~ versus nigral FA in control arm of studies included in the initial meta-analysis.\
The scatter-plot demonstrates that studies with a higher FA in the control arm show the largest variation in disease effect (D~ES~) of PD induced nigral FA changes.](gr3){#f0010}

![Mean diffusivity disease effect size Forest plot.\
Forest plot of the computed diseases effect sizes (D~ES~, x-axis) of different studies on mean diffusivity measures of the substantia nigra when comparing PD patients and controls. In the majority of studies a small increase of MD in PD patients can be observed as indicated by a positive D~ES~.](gr4){#f0015}

###### 

Different types of SN ROI analysis in PD patients and controls.

       Analysis 1 (average of small SN ROI)   Analysis 1b (small dorsal SN ROI)   Analysis 2 (variable size whole SN ROI)                                                                           
  ---- -------------------------------------- ----------------------------------- ----------------------------------------- --------------- --------------- ------- --------------- --------------- -------
  FA   0.44 ± 0.05                            0.45 ± 0.05                         0.39                                      0.45 ± 0.06     0.46 ± 0.05     0.46    0.44 ± 0.04     0.45 ± 0.05     0.43
  MD   0.801 ± 0.102                          0.728 ± 0.064                       0.002                                     0.816 ± 0.097   0.748 ± 0.053   0.002   0.795 ± 0.099   0.732 ± 0.055   0.005

###### 

Overview of studies included in the meta-analysis.

  Study name   FA   MD (ADC)   Scanner make               Field-str.   Head coil   DTI dir.   Voxel size \[mm\]   DTI proc.           M-corr.   Eddy cur.   ROI placem.
  ------------ ---- ---------- -------------------------- ------------ ----------- ---------- ------------------- ------------------- --------- ----------- ----------------
  [@bb0160]    ✓    (✓)        Philips Achieva            3 T          ?           16         0.9 x 0.9 x 3       DTI studio V3.0.3   ?         ?           Manual
  [@bb0060]    ✓               Siemens Magnetom Trio      3 T          8           42         2 x 2 x 2           DTIPrep             ✓         ✓           Manual
  [@bb0205]    ✓    ✓          Philips Intera             1.5 T        16          32         1.8 x 1.8 x 3       FSL                 ✓         ✓           Manual
  [@bb0170]    ✓    ✓          General Electrics          1.5 T        8           31         2.03 x 2.03 x 3     FSL V4.1            ✓         ✓           Manual
  [@bb0235]    ✓    ✓          Siemens Magnetom Trio      3 T          ?           64         2 x 2 x 2           Matlab V7.8         ?         ?           Manual
  [@bb0250]    ✓    ✓          Bruker/Siemens Medspec     4 T          ?           6          2 x 2 x 3           FSL                 ✓         ✓           Semi -- Manual
  [@bb0140]    ✓    ✓          Siemens Trio               3 T          12          60         2 x 2 x 2           FSL                 ✓         ✓           Semi -- Manual
  [@bb0150]    ✓    ✓          Siemens Allegro            3 T          ?           30         1.8 x 1.8 x 1.8     FSL V4              ✓         ✓           Manual
  [@bb0080]         ✓          Siemens Magnetom Avanto    1.5 T        4           12         1.9 x 1.9 x 2.5     ?                   ?         ?           Manual
  [@bb0220]    ✓               General Electrics, Signa   3 T          8           27         0.78 x 0.78 x 4     DTI studio          ✓         ✓           Manual
  [@bb0030]    ✓    (✓)        Siemens Avanto             1.5 T        ?           12         1.2 x 1.2 x 4       ?                   ✓         ✓           Manual
  this study   ✓    ✓          Philips Achieva            3 T          8           32         2 x 2 x 2           FSL V4.1            ✓         ✓           Manual

FA = fractional anisotropy measures extracted from study, MD = mean diffusivity measures extracted from study, Field-str. = Field-strength of magnet, Headcoil = Number of channels within the receiver head coil, DTI dir. = Number of DTI diffusion directions for data acquisition, Voxel size \[mm\] = Size of voxels for acquisition, DTI proc. = Software used to process the DTI data prior to analysis, M-corr = Motion correction used, Eddy cur. = Eddy current correction used, ROI placem. = method of ROI placement. '✓' is used as a positive indicator, '?' is used in unclear cases.

[^1]: N = Number of participants, UPDRS = Unified Parkinson\'s disease rating scale, HY stage = Hoehn and Yahr stage, ? = data not demonstrated in publication.

[^2]: N = Number of participants, SD = Standard deviation, SE = Standard error. Weight = weighting of study for calculation of the pooled weighted estimation of FA D~ES~.

[^3]: MD unit = 10^− 3^ mm^2^/s. The study indicated by \* reported the MD unit = 10^− 6^ mm^2^/s. Studies reporting ADC indicated with brackets. N = Number of participants, SD = Standard deviation, SE = Standard error. Weight = weighting of study for calculation of the pooled weighted estimation of MD D~ES~.
